-
Featured Authors
-
Archives
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Inside BIO Industry Analysis
Biotech Stocks: Perspective in a Bull Market
Investors are increasingly interested in biotechnology based on scientific breakthroughs, an improved regulatory environment, strong earnings growth from large companies, and a more mature industry. Recent advancements in biotechnology are revolutionizing treatments and cures for many illnesses, creating new value for the healthcare system. In 2013, our understanding of how therapeutics can be used to harness the immune system to destroy cancer cells exploded with many companies reporting solid data in human testing. In 2014, Read More >
Biobased Companies Take A Closer Look At Sustainability
BIO and its member companies are constantly working together to help shift the world’s reliance on petroleum-based products to a reliance on biobased and greener products. In a recent piece by Chemical & Engineering News, Melody Bomgardner highlights BIO’s work with it’s member companies to create a more sustainable supply chain in effort create environmentally friendlier products for consumers. Here are some notable points from her piece: “Thanks to the emerging bioeconomy, renewable substances made from plants Read More >
Will We Ever Have Genetically Modified Meat?
Currently, there are no genetically engineered animals sold for human consumption on the market, reports Popular Science. As you might have guessed, the lack of genetically modified meat on the market isn’t because of a lack of technology or safety; it’s because of the politics. GM foods are deeply unpopular as of now, and GM food animals are especially so. After reading an article concerning GM animals from The Scientist showing how effective they can be, Read More >
Bioeconomics: Everybody’s Doing It
It is everywhere. In March, the US State Department held a one-day conference titled “Showcasing the Bioeconomy: The Future is Now”. That same month, the UK House of Lords published a report on the same topic. “Waste could be turned into wealth,” they said. In the past couple of weeks, Finland’s first national bioeconomy strategy was unveiled, while the Borneo Post reported that “The vast potentiality of bioeconomy has been regarded as one of the Read More >
Therapeutic Licensing and M&A Deals
Licensing deals for therapeutic candidates in 2013 dropped to the lowest volume in at least eight years for deals with disclosed values totaling over $10M. Total upfront payments to biotechs were also at an eight year low, with only $1.9B paid to biotechs in 2013. This is a 50 percent drop from peak levels. However, there is a silver lining in the data: Preclinical deal volume saw a slight increase in 2013, and has not Read More >
